Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

  
 
  
Reply to this topic

BDX, BCAL DIAGNOSTICS LIMITED
nipper
post Posted: Jul 21 2021, 12:20 PM
  Quote Post


Posts: 9,526
Thanks: 2779


In Reply To: nipper's post @ Jul 19 2021, 06:46 PM

BDX made it to the ASX today..... Trading around its IPO price at 25c



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jul 19 2021, 06:46 PM
  Quote Post


Posts: 9,526
Thanks: 2779


In Reply To: nipper's post @ Jul 5 2021, 07:47 PM

https://stockhead.com.au/ipo-watch/ipo-watc...-asx-next-week/

QUOTE
A growing trend in healthcare has been replacing various forms of invasive tests with blood tests, and BCAL Diagnostics (ASX:BDX) is the next in line to join the cohort.

BCAL Diagnostics has spent nearly a decade developing a blood test to detect breast cancer and is listing on the ASX on Wednesday having raised $10 million at 25 cents per share.

Rhythm Biosciences (ASX:RHY) is another company working on a blood test to detect cancer – specifically colorectal cancer.

This company listed in 2017 and after a slow couple of years is up 360 per cent since listing as it pushed closer to the long promised clinical trial.

BCAL’s listing comes little over a fortnight after the listing of Lumos Diagnostics (ASX:LDX) which also has a finger-prick blood test but for respiratory diseases generally......





--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jul 5 2021, 07:47 PM
  Quote Post


Posts: 9,526
Thanks: 2779


BCAL Diagnostics Ltd (BDX) was established in 2010 as looking to list on the ASX in July 2021. BCAL Diagnostics aims to shift the paradigm in breast cancer screening and diagnosis by introducing a blood test for detection of the disease.

BCAL is developing a non invasive laboratory blood test for the detection of breast cancer. The core BCAL technology has evolved from extensive research and investment over approximately ten years by independent groups based in the USA and Australia.

Researchers from the University of Louisville Research Foundation, Inc (ULRF) were able to show that breast cancer patient samples contain significantly different lipid profiles from those of both healthy volunteers and lung cancer patients; using a defined methodology. In 2011 ULRF filed a patent application using this data. Working independently in Sydney, BCAL's science team observed a similar trend in their own research, and as a result the Company decided in 2013 to license the technology the subject of a patent application from ULRF.

While BCAL's first objective is to secure TGA approval for use of a test based on this information used alongside mammography, the Company's data and clinical trials are designed to facilitate sequential market entry points. The purpose of the Company has been, since inception, to achieve a sequential series of claims or uses for its test as follows, each of which depends on confirmatory data from successful clinical trials of BCAL's technology, as:

(1) a screening test for breast cancer alongside mammography;
(2) a monitoring tool for breast cancer patients who have been given the all clear following treatment; and
(3) monitoring and screening for women who have the BRCA gene mutation, or are otherwise at high risk of developing breast cancer.

Ultimately, the clinical data and clinical trials will be utilised and assessed for their clinical utility by leading global key opinion leaders in the breast cancer diagnostic and treatment field. Successive regulatory approvals and marketing of the BCAL test for a widening range of indications will move BCAL towards its end goal of introducing a breast cancer screening blood test for every woman, everywhere.

Listing date... 16 July 2021 #

Contact details .... https://www.bcaldiagnostics.com/
Principal Activities... BCAL Diagnostics Limited is a biotechnology company developing a blood based diagnostic test for breast cancer.

Issue Price... $0.25
Issue Type... Ordinary Fully Paid Shares
Security code... BDX
Capital to be Raised... $8,000,000

Expected offer close date.... 02 Jul 2021
Underwriter.... Not underwritten. PAC Partner Securities Pty Ltd (Lead Manager)



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
 



Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING